Fulcrum Therapeutics (FULC) Net Margin (2020 - 2024)
Historic Net Margin for Fulcrum Therapeutics (FULC) over the last 5 years, with Q2 2024 value amounting to 69.26%.
- Fulcrum Therapeutics' Net Margin rose 27718700.0% to 69.26% in Q2 2024 from the same period last year, while for Mar 2025 it was 21.43%, marking a year-over-year increase of 39826300.0%. This contributed to the annual value of 12.16% for FY2024, which is 34579000.0% up from last year.
- Fulcrum Therapeutics' Net Margin amounted to 69.26% in Q2 2024, which was up 27718700.0% from 2842.25% recorded in Q4 2023.
- Over the past 5 years, Fulcrum Therapeutics' Net Margin peaked at 69.26% during Q2 2024, and registered a low of 8399.66% during Q1 2023.
- In the last 5 years, Fulcrum Therapeutics' Net Margin had a median value of 1026.08% in 2020 and averaged 1885.27%.
- As far as peak fluctuations go, Fulcrum Therapeutics' Net Margin plummeted by -73993500bps in 2023, and later soared by 27718700bps in 2024.
- Fulcrum Therapeutics' Net Margin (Quarter) stood at 419.41% in 2020, then decreased by -11bps to 464.29% in 2021, then plummeted by -722bps to 3815.33% in 2022, then rose by 26bps to 2842.25% in 2023, then skyrocketed by 102bps to 69.26% in 2024.
- Its last three reported values are 69.26% in Q2 2024, 2842.25% for Q4 2023, and 3164.3% during Q3 2023.